TY - JOUR
T1 - Association of Alzheimer disease pathology with abnormal lipid metabolism
T2 - The hisayama study
AU - Matsuzaki, T.
AU - Sasaki, K.
AU - Hata, J.
AU - Hirakawa, Y.
AU - Fujimi, K.
AU - Ninomiya, T.
AU - Suzuki, S. O.
AU - Kanba, S.
AU - Kiyohara, Y.
AU - Iwaki, T.
N1 - Funding Information:
Dr. Matsuzaki reports no disclosures. Dr. Sasaki receives research support from Grant-in-Aid for Scientific Research (C) from Japan Society for the Promotion of Science and Grant-in-Aid for Scientists from the Ministry of Health, Labour and Welfare, Japan. Dr. Hata, Dr. Hirakawa, Dr. Fujimi, Dr. Ninomiya, and Dr. Suzuki report no disclosures. Dr. Kanba serves on a scientific advisory board for Astellas Pharma Inc.; serves/has served on editorial advisory boards for Molecular Psychiatry, the Journal of Neuroscience and Psychiatry, the Asian Journal of Psychiatry, and the Asia Pacific Journal of Psychiatry; has received speaker honoraria from Janssen, Shanghai Tsumura Pharmaceuticals Co., Ltd., Ajinomoto Co., Inc., Yoshitomi Pharmaceutical Industries, Ltd., Meiji Seika Pharma Co., Ltd, Kyowa-Hakko, Dainippon Sumitomo Pharma Co., Ltd., Organon Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc, Asahi Kasei Kuraray Medical Co., Ltd., and Shionogi & Co., Ltd.; has served as consultant for Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc, Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co. Ltd., Astellas Pharma Inc., Asahi-kasei, Shionogi, and Otsuka Pharmaceutical Co., Ltd.; and receives/has received research support from has received research support from Eli Lilly and Company, GlaxoSmithKline, Pfizer Inc, Asahi Kasei Kuraray Medical Co., Ltd., Janssen, Shanghai Tsumura Pharmaceuticals Co., Ltd., Ajinomoto Co., Inc., Yoshitomi Pharmaceutical Industries, Ltd., Meiji Seika Pharma Co., Ltd, Kyowa Hakko Kirin Pharma, Inc., Dainippon Sumitomo Pharma Co., Ltd., Organon Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co. Ltd., and Japanese Ministry of Education and of Health. Dr. Kiyohara receives research support from a Health and Labour Sciences Research Grant of the Ministry of Health, Labour and Welfare, Japan. Dr. Iwaki serves as an Associate Editor for Brain Tumor Pathology and on the editorial boards of Neuropathology, Pathology-Research and Practice, and Pathology International; and receives research support from a Grant-in-Aid for Scientific Research (B) from Japan Society for the Promotion of Science (JSPS).
Funding Information:
Study funding: Supported by a Grant-in-Aid for Scientific Research (B) (No. 22300116 and (C) (No. 21500337 )) from Japan Society for the Promotion of Science (JSPS) and by a Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan (Comprehensive Research on Aging and Health: H20-Chouju-004). The funders of the present study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
PY - 2011/9/13
Y1 - 2011/9/13
N2 - Objective: The relationship between lipid profiles and Alzheimer disease (AD) pathology at the population level is unclear. We searched for evidence of AD-related pathologic risk of abnormal lipid metabolism. Methods: This study included brain specimens from a series of 147 autopsies performed between 1998 and 2003 of residents in Hisayama town, Japan (76 men and 71 women), who underwent clinical examinations in 1988. Lipid profiles, such as total cholesterol (TC), triglycerides, and high-density lipoprotein cholesterol (HDLC), were measured in 1988. Low-density lipoprotein cholesterol (LDLC) was calculated using the Friedewald formula. Neuritic plaques (NPs) were assessed according to the Consortium to Establish a Registry for Alzheimer's Disease guidelines (CERAD) and neurofibrillary tangles (NFTs) were assessed according to Braak stage. Associations between each lipid profile and AD pathology were examined by analysis of covariance and logistic regression analyses. Results: Adjusted means of TC, LDLC, TC/HDLC, LDLC/HDLC, and non-HDLC (defined as TC- HDLC) were significantly higher in subjects with NPs, even in sparse to moderate stages (CERAD = 1 or 2), compared to subjects without NPs in multivariate models including APOE ε4 carrier and other confounding factors. The subjects in the highest quartiles of these lipid profiles had significantly higher risks of NPs compared to subjects in the lower respective quartiles, which may suggest a threshold effect. Conversely, there was no relationship between any lipid profile and NFTs. Conclusion: The results of this study suggest that dyslipidemia increases the risk of plaque-type pathology.
AB - Objective: The relationship between lipid profiles and Alzheimer disease (AD) pathology at the population level is unclear. We searched for evidence of AD-related pathologic risk of abnormal lipid metabolism. Methods: This study included brain specimens from a series of 147 autopsies performed between 1998 and 2003 of residents in Hisayama town, Japan (76 men and 71 women), who underwent clinical examinations in 1988. Lipid profiles, such as total cholesterol (TC), triglycerides, and high-density lipoprotein cholesterol (HDLC), were measured in 1988. Low-density lipoprotein cholesterol (LDLC) was calculated using the Friedewald formula. Neuritic plaques (NPs) were assessed according to the Consortium to Establish a Registry for Alzheimer's Disease guidelines (CERAD) and neurofibrillary tangles (NFTs) were assessed according to Braak stage. Associations between each lipid profile and AD pathology were examined by analysis of covariance and logistic regression analyses. Results: Adjusted means of TC, LDLC, TC/HDLC, LDLC/HDLC, and non-HDLC (defined as TC- HDLC) were significantly higher in subjects with NPs, even in sparse to moderate stages (CERAD = 1 or 2), compared to subjects without NPs in multivariate models including APOE ε4 carrier and other confounding factors. The subjects in the highest quartiles of these lipid profiles had significantly higher risks of NPs compared to subjects in the lower respective quartiles, which may suggest a threshold effect. Conversely, there was no relationship between any lipid profile and NFTs. Conclusion: The results of this study suggest that dyslipidemia increases the risk of plaque-type pathology.
UR - http://www.scopus.com/inward/record.url?scp=80155141526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80155141526&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e31822e145d
DO - 10.1212/WNL.0b013e31822e145d
M3 - Article
C2 - 21911734
AN - SCOPUS:80155141526
SN - 0028-3878
VL - 77
SP - 1068
EP - 1075
JO - Neurology
JF - Neurology
IS - 11
ER -